Note 13 - Subsequent Events	6 Months Ended
Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	( 13 ) Subsequent Events On July 5, 2019, BioCardia entered into a note purchase agreement pursuant to which the Company issued on such date $625,000 in aggregate principal amount of convertible promissory notes to accredited investors, a portion of which were certain of the Company’s officers and directors and a principal stockholder (or their respective affiliates). Interest on the convertible notes accrues at the rate of 14.0% per year. Upon the closing of the Company’s public offering of units on August 6, 2019 the unpaid principal and interest on the convertible notes totaling approximately $633,000, converted into 210,887 units, unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a conversion price of $3.00 per unit. On July 11, 2019, BioCardia signed an extension to a 2017 development agreement with a global biotherapeutics leader for BioCardia’s Helix™ biotherapeutic delivery catheter system. The agreement is exclusive with respect to a class of biotherapeutic agents that BioCardia is not currently developing on its own or with any other party and is time limited. Under the terms of the initial pre-clinical phase of the relationship, BioCardia received an upfront payment of $1,000,000 on August 13, 2019, a portion of which will be creditable to BioCardia biotherapeutic delivery systems, support and training. On August 2, 2019, the Company entered into an underwriting agreement with Maxim Group LLC, as representative of the several underwriters name therein, related to a firm commitment underwritten public offering pursuant to the S- 1, of 1,666,667 units consisting of one share of common stock, par value of $0.001 per share, and a warrant to purchase one share of common stock. The offering price to the public was $6.00 per unit. The warrants are immediately exercisable for shares of common stock at a price of $6.30 per share and expire five years from the date of issuance. The offering price to the public of $6.00 resulted in total gross proceeds of $10.0 million. The net proceeds realized by the Company is approximately $8.76 million, after deducting estimated offering expenses of $635,000 and underwriting discounts and commissions of approximately $610,000. BioCardia has granted to the underwriters a 45 -day option to purchase up to 250,000 additional shares of common stock, and/or 250,000 additional warrants to cover over-allotments, if any. On August 2, 2019 the Company’s common stock and warrants to purchase common stock began trading on the Nasdaq Capital Market. Previously the common stock was quoted on the OTCQB Marketplace (OTCQB) under the symbol, “BCDA”. “BCDA” and “BCDAW” are the trading symbols for the Company’s common stock and warrants to purchase common stock, respectively, on the Nasdaq Capital Market.

(

) Subsequent Events

July 5, 2019,

BioCardia entered into a note purchase agreement pursuant to which the Company issued on such date

$625,000

in aggregate principal amount of convertible promissory notes to accredited investors, a portion of which were certain of the Company’s officers and directors and a principal stockholder (or their respective affiliates). Interest on the convertible notes accrues at the rate of

14.0%

per year. Upon the closing of the Company’s public offering of units on

August 6, 2019

the unpaid principal and interest on the convertible notes totaling approximately

$633,000,

converted into

210,887

units, unit consisting of

one

share of common stock and a warrant to purchase

one

share of common stock, at a conversion price of

$3.00

per unit.

July 11, 2019,

BioCardia signed an extension to a

2017

development agreement with a global biotherapeutics leader for BioCardia’s Helix™ biotherapeutic delivery catheter system. The agreement is exclusive with respect to a class of biotherapeutic agents that BioCardia is

not

currently developing on its own or with any other party and is time limited. Under the terms of the initial pre-clinical phase of the relationship, BioCardia received an upfront payment of

$1,000,000

August 13, 2019,

a portion of which will be creditable to BioCardia biotherapeutic delivery systems, support and training.

August 2, 2019,

the Company entered into an underwriting agreement with Maxim Group LLC, as representative of the several underwriters name therein, related to a firm commitment underwritten public offering pursuant to the S-

1,666,667

units consisting of

one

share of common stock, par value of

$0.001

per share, and a warrant to purchase

one

share of common stock. The offering price to the public was

$6.00

per unit. The warrants are immediately exercisable for shares of common stock at a price of

$6.30

per share and expire

five

years from the date of issuance. The offering price to the public of

$6.00

resulted in total gross proceeds of

$10.0

million. The net proceeds realized by the Company is approximately

$8.76

million, after deducting estimated offering expenses of

$635,000

and underwriting discounts and commissions of approximately

$610,000.

BioCardia has granted to the underwriters a

-day option to purchase up to

250,000

additional shares of common stock, and/or

250,000

additional warrants to cover over-allotments, if any.

August 2, 2019

the Company’s common stock and warrants to purchase common stock began trading on the Nasdaq Capital Market. Previously the common stock was quoted on the OTCQB Marketplace (OTCQB) under the symbol, “BCDA”. “BCDA” and “BCDAW” are the trading symbols for the Company’s common stock and warrants to purchase common stock, respectively, on the Nasdaq Capital Market.